The latter result being the end result of zoledronate as opposed to the one of everolimus. Like osteosarcoma, chondrosarcoma is characterized by a tumefaction induced osteolysis, more over, Ubiquitin conjugation inhibitor zoledronate has proven to be an effective agent in the same chondrosarcoma model. Thus it seems pertinent to hypothesize that the mixture of everolimus to zoledronate could possibly be efficient within this tumor. Such combined therapies are worth exploring in pre-clinical settings. In conclusion, the current results show that everolimus will be a successful anti-tumor agent in chondrosarcoma. Besides, the inhibition of tumor regrowth following surgery suggests that everolimus could be used as adjuvant long haul treatment in chondrosarcoma patients following surgery. These results open the method to new therapeutic strategies and resulted in a prospective phase II clinical trial initiatied inside the French Sarcoma Group. Metastatic prostate cancer, by progressing to castrationresistant CaP, represents a major threat to the life of American males, resulting in estimated 28,170 deaths Posttranslational modification (PTM) from this disease in 2012. Patients with metastatic CaP are often treated with androgen deprivation therapy. Unfortuitously, failure of ADT inevitably occurs and the in-patient s tumefaction becomes CRPC. It is known that throughout CRPC development CaP cells use a number of androgen receptor dependent and independent pathways to survive and flourish in an androgen depleted environment. Even though several attempts have already been built to characterize the molecular signature of CRPC, the particular mechanisms leading to CRPC aren’t completely understood. In the past few years, the discovery of microRNAs has discovered a new level of complexity that controls the elements involved in regulating CRPC. MicroRNAs are small non coding RNAs that function HDAC inhibitors list as collection unique regulators of gene expression through translational repression and/or transcript bosom. Studies have shown that miRNAs play critical roles in cellular processes of differentiation, proliferation, apoptosis and metabolic homeostasis. Furthermore, miRNAs can work as either tumor suppressors or oncogenes, based on whether they especially target oncogenes or tumor suppressor genes. In this regard, tumor suppressive miRNAs are usually under expressed while oncogenic miRNAs tend to be over expressed in cancer. Studies demonstrate that miR 125b is oncogenic. Overexpression of miR 125b was reported in colon cancer, bladder cancer, ovarian cancer and leukemia. We previously reported that medical CaP tumors show increased levels of miR 125b compared to benign tissues. Moreover, a few studies have indicated that miR 125b is highly expressed in CaP, specially in metastatic and invasive CaP tumors.